The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

(2012) William Kevin Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature

(2011) Guru Sonpavde et al.   EUROPEAN UROLOGY

New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety

(2011) Himisha Beltran et al.   EUROPEAN UROLOGY

EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer

(2011) Nicolas Mottet et al.   EUROPEAN UROLOGY

Current Vaccination Strategies for Prostate Cancer

(2011) Steven Joniau et al.   EUROPEAN UROLOGY

Expanding Treatment Options for Metastatic Prostate Cancer

(2011) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer

(2011) E S Antonarakis et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Characteristics and Outcomes of Patients With Advanced Gastric Cancer Who Declined to Participate in a Randomized Clinical Chemotherapy Trial

(2011) Chiharu Tanai et al.   Journal of Oncology Practice

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials

(2009) C Tanai et al.   BRITISH JOURNAL OF CANCER

Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer

(2009) A. J. Armstrong et al.   CLINICAL CANCER RESEARCH

Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer

(2009) Jianqing Lin et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Influence of Clinical Communication on Patients' Decision Making on Participation in Clinical Trials

(2008) Terrance L. Albrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY